Researchers at the University of Wisconsin–Madison have developed a high-throughput platform to screen nearly all of the more than 19,000 human genes, identifying those that hinder the success of CRISPR-Cas9 gene editing. Published in Nature Communications on August 13, 2026, the work provides a critical roadmap for improving nonviral genetic editing technologies—particularly for treating genetic eye diseases where delivery and editing efficiency remain major barriers.
This breakthrough builds on a wave of CRISPR innovation. Scientists at the University of Florida recently developed the world's first DNA-guided CRISPR system, which uses stable DNA guides instead of RNA to target genetic material with greater precision and lower cost. Meanwhile, researchers from Purdue and Columbia universities discovered a natural CRISPR variant that turns genes on without cutting DNA which basically is a gentler alternative that could lead to safer medical treatments.
AI is also accelerating the field: Stanford Medicine's CRISPR-GPT helps researchers plan experiments faster, cutting drug development timelines from years to months. The UW–Madison platform now adds another layer by revealing which genes act as roadblocks, enabling researchers to bypass them and unlock CRISPR's full therapeutic potential.